미국의 항바이러스제 시장 규모, 점유율, 동향 분석 보고서 : 유형별, 약제 클래스별, 유통 채널별, 부문별 예측(2025-2030년)

U.S. Antiviral Drugs Market Summary

The U.S. antiviral drugs market size was estimated at USD 26.41 billion in 2024 and is projected to reach USD 23.61 billion by 2030, growing at a CAGR of -1% from 2025 to 2030. This decline is largely due to the waning demand for COVID-19-specific antivirals, as the number of severe COVID-19 cases and related hospitalizations has dropped significantly in 2025.

Treatments for HIV, hepatitis B and C, herpes, and influenza primarily drive the U.S. market for antiviral drugs. The CDC estimates that about 1.2 billion people in the U.S. are living with HIV, 2.4 billion with hepatitis C, and 850,000 with hepatitis B. The CDC reports that acute respiratory illnesses, including influenza, COVID-19, and RSV, remain at very low levels in the U.S. as of mid-2025, reducing the immediate demand for antiviral medications. This low incidence, combined with the growing use of complementary health approaches for symptom relief and immune support, has moderated the growth of the antiviral drugs market.

Despite these advancements, the high cost of antiviral treatments remains a significant challenge for many patients and healthcare systems in the U.S. For instance, the hepatitis C drug Sovaldi costs approximately USD 1,000 per pill, resulting in a total treatment cost of around USD 84,000 for a 12-week course . Similarly, Olysio's monthly treatment cost is estimated at USD 23,600, with treatment durations extending up to 48 weeks.

Regulatory oversight by the U.S. Food and Drug Administration (FDA) plays an essential role in shaping the antiviral drugs industry. The FDA's rigorous approval process ensures safety and efficacy, with recent approvals emphasizing combination therapies and pediatric indications. In June 2025, the FDA approved the expanded use of Mavyret for acute hepatitis C in children aged 3 and above.

U.S. Antiviral Drugs Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global U.S. antiviral drugs industry report based on type, drug class, application, and distribution channel.

• Type Outlook (Revenue, USD Billion, 2018 - 2030)
• Branded
• Generics
• Drug Class Outlook (Revenue, USD Billion, 2018 - 2030)
• DNA Polymerase Inhibitors
• Reverse Transcriptase Inhibitors
• Protease Inhibitors
• Neuraminidase Inhibitors
• Others
• Application Outlook (Revenue, USD Billion, 2018 - 2030)
• HIV
• Hepatitis
• Herpes
• Influenza
• Others
• Distribution Channel Outlook (Revenue, USD Billion, 2018 - 2030)
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Type
  • 1.2.2. Drug Class
  • 1.2.3. Application
  • 1.2.4. Distribution Channel
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Type
  • 2.2.2. Drug Class
  • 2.2.3. Application
  • 2.2.4. Distribution Channel
• 2.3. Competitive Insights

Chapter 3. U.S. Antiviral Drugs Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
  • 3.2.2. Market restraint analysis
• 3.3. U.S. Antiviral Drugs Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape
• 3.4. U.S. Antiviral Drugs Market: Pipeline Analysis

Chapter 4. U.S. Antiviral Drugs Market: Type Estimates & Trend Analysis

• 4.1. Type Segment Dashboard
• 4.2. U.S. Antiviral Drugs Market: Type Movement Analysis
• 4.3. U.S. Antiviral Drugs Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Billion)
• 4.4. Branded
  • 4.4.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
• 4.5. Generics
  • 4.5.1. Market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 5. U.S. Antiviral Drugs Market: Drug Class Estimates & Trend Analysis

• 5.1. Drug Class Segment Dashboard
• 5.2. U.S. Antiviral Drugs Market: Drug Class Movement Analysis
• 5.3. U.S. Antiviral Drugs Market Size & Trend Analysis, by Drug Class, 2018 to 2030 (USD Billion)
• 5.4. DNA Polymerase Inhibitors
  • 5.4.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
• 5.5. Reverse Transcriptase Inhibitors
  • 5.5.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
• 5.6. Protease Inhibitors
  • 5.6.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
• 5.7. Neuraminidase Inhibitors
  • 5.7.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
• 5.8. Others
  • 5.8.1. Market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 6. U.S. Antiviral Drugs Market: Application Estimates & Trend Analysis

• 6.1. Application Segment Dashboard
• 6.2. U.S. Antiviral Drugs Market: Application Movement Analysis
• 6.3. U.S. Antiviral Drugs Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Billion)
• 6.4. HIV
  • 6.4.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
• 6.5. Hepatitis
  • 6.5.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
• 6.6. Herpes
  • 6.6.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
• 6.7. Influenza
  • 6.7.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
• 6.8. Others
  • 6.8.1. Market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 7. U.S. Antiviral Drugs Market: Distribution Channel Estimates & Trend Analysis

• 7.1. Distribution Channel Segment Dashboard
• 7.2. U.S. Antiviral Drugs Market: Distribution Channel Movement Analysis
• 7.3. U.S. Antiviral Drugs Market Size & Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Billion)
• 7.4. Hospital Pharmacy
  • 7.4.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
• 7.5. Retail Pharmacy
  • 7.5.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
• 7.6. Online Pharmacy
  • 7.6.1. Market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
• 8.3. Vendor Landscape
  • 8.3.1. Key company heat map analysis, 2024
• 8.4. Company Profiles
  • 8.4.1. F. Hoffmann-La Roche Ltd.
    • 8.4.1.1. Company overview
    • 8.4.1.2. Financial performance
    • 8.4.1.3. Product benchmarking
    • 8.4.1.4. Strategic initiatives
  • 8.4.2. GSK plc.
    • 8.4.2.1. Company overview
    • 8.4.2.2. Financial performance
    • 8.4.2.3. Product benchmarking
    • 8.4.2.4. Strategic initiatives
  • 8.4.3. AbbVie, Inc.
    • 8.4.3.1. Company overview
    • 8.4.3.2. Financial performance
    • 8.4.3.3. Product benchmarking
    • 8.4.3.4. Strategic initiatives
  • 8.4.4. Merck & Co., Inc.
    • 8.4.4.1. Company overview
    • 8.4.4.2. Financial performance
    • 8.4.4.3. Product benchmarking
    • 8.4.4.4. Strategic initiatives
  • 8.4.5. Johnson & Johnson Services, Inc.
    • 8.4.5.1. Company overview
    • 8.4.5.2. Financial performance
    • 8.4.5.3. Product benchmarking
    • 8.4.5.4. Strategic initiatives
  • 8.4.6. Bristol-Myers Squibb Company
    • 8.4.6.1. Company overview
    • 8.4.6.2. Financial performance
    • 8.4.6.3. Product benchmarking
    • 8.4.6.4. Strategic initiatives
  • 8.4.7. Cipla Inc.
    • 8.4.7.1. Company overview
    • 8.4.7.2. Financial performance
    • 8.4.7.3. Product benchmarking
    • 8.4.7.4. Strategic initiatives
  • 8.4.8. Aurobindo Pharma
    • 8.4.8.1. Company overview
    • 8.4.8.2. Financial performance
    • 8.4.8.3. Product benchmarking
    • 8.4.8.4. Strategic initiatives
  • 8.4.9. Dr. Reddy's Laboratories Ltd.
    • 8.4.9.1. Company overview
    • 8.4.9.2. Financial performance
    • 8.4.9.3. Product benchmarking
    • 8.4.9.4. Strategic initiatives
  • 8.4.10. ADARx Pharmaceuticals Inc.
    • 8.4.10.1. Company overview
    • 8.4.10.2. Financial performance
    • 8.4.10.3. Product benchmarking
    • 8.4.10.4. Strategic initiatives